Hypothesis: The age-associated accumulation of T-helper cells that naturally clear senescent cells can be therapeutically primed to enhance the efficacy of low-dose senolytics, reducing off-target toxicity while promoting tissue rejuvenation.

Background: Senescent cells drive aging and disease via SASP, but current senolytics like dasatinib+quercetin have imperfect specificity Senolytics as Modulators of Critical Signaling Pathways. A subset of T-helper cells accumulates with age and appears to clear senescent cells endogenously Neuroscientists find immune cells that may slow aging, suggesting an untapped synergy. Recent machine learning has identified novel senolytics, such as panaxatriol, with targeted mechanisms Development and Application of a Senolytic Predictor, yet optimal dosing remains elusive due to off-target effects.

Mechanistic Rationale: Brief SASP exposure can stimulate beneficial immunity and cellular reprogramming The interplay of cellular senescence and reprogramming, so controlled SASP modulation might attract T-helper cells to senescent niches. For instance, transient IL-6 or IL-8 release could upregulate chemokines like CXCL9, guiding T-helper cell infiltration. Simultaneously, low-dose senolytics—particularly those targeting BCL-2 family proteins or modulati

Hypothesis: The skeleton acts as an endocrine regulator of multicellular fidelity, actively suppressing atavistic cancer programs through bone-derived osteocalcin (OCN) and sclerostin. Age-related decline in skeletal endocrine output removes a critical checkpoint that maintains repression of ancient unicellular survival programs, enabling the epigenetic de-repression events described in the atavistic theory.

Mechanistic Framework:

What actively maintains suppression of these ancient programs in healthy tissue? The atavistic theory itself doesn't address this. We believe bone-derived factors fill this systemic regulatory role.

Cancer, according to the atavistic model, represents reversion to phylostrata 1-2 gene expression programs through epigenetic de-repression of TERT, Wnt/β-catenin pathway hijacking, and metabolic reversion to glycolysis. But there's a gap in the literature—what keeps these programs silenced in normal tissue?

Osteocalcin Mechanism: OCN binds to GPR37L1 in neural tissue and regulates p53-Sp1 interactions critical for TERT suppression. Our hypothesis is that OCN enhances p53 transcriptional activity at the TERT promoter while disrupting Sp1-mediated activation, maintaining CTCF complex integrity. When OCN declines with age (roughly 30-50% reduction from ages 30 to 80), this suppression lifts. That's when ETS transcription factors can bind and reactivate TERT—the pattern we see in 85-95% of cancers.

Sclerostin Mechanism: Osteocyte-derived sclerostin inhibits Wnt/β-catenin signaling, a pathway that cancer specifically hijacks to induce

Background

Pharmacogenomics in rheumatology has been developed almost exclusively in European and East Asian populations. Only 26% of clinically relevant pharmacogenetic biomarkers have been studied in Mexican populations (Gonzalez-Covarrubias et al., Front Pharmacol 2016, PMID: 26812836). For Indigenous American populations specifically, the gaps are near-total.

Hypothesis

A targeted 12-gene pharmacogenomic panel, designed around the treatment patterns observed in 607 autoimmune patients from a Maya-mestizo population, would fill the single largest gap in rheumatology pharmacogenomics globally — and could fundamentally alter treatment algorithms for the 130+ million people of Indigenous American ancestry across the Americas.

The Clinical Foundation: 607 Patients, 4 Disease Cohorts

This framework emerges from real-world treatment patterns across 4 cohorts at a single IMSS institution in southeastern Mexico (estimated 60-75% Indigenous Maya ancestry):

We've spent decades treating caloric restriction (CR) as the gold standard for living longer. But longevity science remains obsessed with "solo actors," treating CR as a universal lever while ignoring the messy epistatic architecture of the genome. Recent data suggests CR's efficacy isn't just genotype-dependent in models like C. elegans—it’s likely shaped by how complex an organism's environment is. I suspect CR and environmental enrichment (EE) are redundant signals that hit the same genetic hubs. This leads to a "ceiling effect" where the perks of CR simply vanish in populations that are already socially and cognitively active.

Mechanistic Insight: Convergent Signaling Hubs

I'm looking at how epistatic SNP-SNP interactions within the insulin/IGF-1 signaling (IIS) and mTOR pathways act as cross-modal integrators. Hubs like GHSR-PTPN1 and FOXO3-CDKN2B—which show up frequently in long-lived cohorts—don't just sense nutrient levels.

Think of it as a Signal Saturation Model:

1. The Metabolic Signal: CR activates these hubs by dialing down IIS tone and boosting stress-response genes like Mafa and Atf6 CR's transcriptomic effects in beta cells.
2. The Environmental Signal: EE (socializing, learning, purpose) kicks off neuro-hormonal cascades—likely via oxytocin and BDNF—that use that same epistatic machine

In mammalian biology, we’re seeing epigenetic clocks less as simple timers and more as ledgers for the metabolic price of staying organized against entropy. I suspect that in colonial marine invertebrates like scleractinian corals, the "epigenetic clock" represents a mounting debt of regulatory stability. It’s a trade-off where the organism sacrifices long-term integration for immediate survival.

Unlike mammals, which use Yamanaka-like resets during gametogenesis to wipe the slate clean, corals don’t have a reset button. They pass stress-induced methylation marks directly to their offspring. Because they can't declare biological bankruptcy, they just keep racking up epigenetic debt. I’d argue that methylation drift—the shift from precise regulatory control to stochastic noise—is the physical signature of a host diverting energy away from DNA maintenance. When a coral is under pressure, it stops investing in DNA methyltransferase fidelity so it can pour resources into acute defenses, like producing carbon-rich mucus to manage its microbial boundary layer. Drift isn't just random error; it’s a prioritized divestment.

We know from human data that a messy microbiome correlates with faster epigenetic aging. In corals, this relationship is likely a lethal, two-way street. As the host loses the ability to pay the "coherence cost" of its own genome, it can no longer regulate its microbiome through targeted signaling or mucus chemistry. This leads to a spike in microbial entropy, which then forces the host to spend even more energy on defense. It’s a debt spiral where the holobion

Hypothesis: Beta cell proteostasis failure in type 2 diabetes is driven by the collapse of a feedforward regulatory loop between UPR branches and amyloid-prone proteins, accelerated by age-dependent erosion of network robustness.

Mechanistic Rationale

The temporal decline of ATF6α and spliced XBP1 during hyperglycemia PMC3920274 isn’t just a passive failure; it’s a critical switch that unleashes IAPP misfolding. Early insulin resistance triggers sXBP1 upregulation as an adaptive response, but as aging reduces transcription factors like PDX1 and NKX6-1 abo3932, protein synthesis rates soar, overloading the ER. This creates a feedforward loop: UPR components normally chaperone IAPP folding, but their decline allows IAPP oligomers to form, which then directly impair ER function—further suppressing UPR. Network analysis shows feedforward interactions are harder to identify and more vulnerable to disruption than feedback loops PMC11341918, suggesting beta cells might rely on a precarious feedforward motif linking PDX1-dependent transcription to UPR activation and IAPP processing. With age, weaker regulatory interactions in this network fail, allowing small perturbations (e.g., hyperglycemia) to trigger irreversible collapse.

Testable Predictions

• Prediction 1: In young beta cells, pharmacological inhibition of ATF6α should accelerate IAPP aggregation even under normal glucose conditions, while ATF6α overexpressi

The prevailing view holds that gut dysfunction in aging stems primarily from intrinsic ENS senescence or microbiome-driven processes. But what if this assumption gets the directionality wrong? I'm arguing that CNS aging actually withdraws trophic maintenance support from the ENS through three interconnected pathways.

Cholinergic Trophic Withdrawal. Vagal efferents supply essential neurotrophic support to ENS neurons via acetylcholine and neurokine signaling. Age-related decline in DMV neuronal activity diminishes this input—this likely accounts for the well-documented 50-60% loss of enteric neurons in aging.

Homeostatic Setpoint Reset. The gut's baseline motility, barrier integrity, and microbiome composition appear to depend on continuous CNS-derived modulatory signals. As vagal tone declines, the gut shifts toward a pro-inflammatory, dysbiotic state—effects that have been mistakenly attributed to primary gut aging.

Afferent Feedback Disruption. We shouldn't forget that reduced efferent signaling also impairs vagal afferent signaling, breaking the bidirectional communication essential for gut-brain homeostasis.

These predictions can be tested: selective DMV lesions in young mice should replicate aged gut phenotypes—colonic transit slowing, barrier dysfunction, dysbiosis—within weeks, mirroring the 66-hour versus 39-hour transit time differential seen in aging. Longitudinal PET imaging should reveal DMV hypometabolism preceding detectable gut transit changes. Optogenetic or chemogenetic activation of vagal efferents in aged animals could reverse ENS neuron l

Background

Psoriatic arthritis (PsA) flares are notoriously unpredictable, with current clinical assessments (DAPSA, MDA) capturing disease activity only at the point of clinical presentation. Sweat contains a rich proteomic milieu that mirrors systemic inflammatory states with minimal invasiveness. Recent advances in wearable microfluidic biosensors enable continuous, real-time quantification of cytokines at picomolar concentrations from eccrine sweat.

Hypothesis

Continuous monitoring of sweat IL-17A and TNF-α concentrations via wearable microfluidic immunoassay patches will reveal characteristic disruptions in circadian oscillation amplitude and phase — specifically, a loss of the normal nocturnal IL-17A nadir and a >2-fold increase in the TNF-α acrophase-to-nadir ratio — that precede PsA flares by 3–6 weeks before patients report joint symptoms or meet DAPSA worsening criteria.

Mechanistic Rationale

IL-17A, the dominant effector cytokine in psoriatic disease, exhibits circadian regulation via RORγt transcription factor coupling to the molecular clock (BMAL1/CLOCK). Pre-flare Th17 expansion should disrupt this circadian gating, producing a measurable "chronotype shift" in sweat IL-17A before systemic inflammatory burden reaches clinical detection thresholds. TNF-α amplifies IL-17A signaling via NF-κB-mediated positive feedback; its ratio dynamics serve as a second independent signal confirming immune activation trajectory.

Testable Predictions

1. Circadian disruption precedes clinical flare: Loss of >50% IL-17A diurnal amplitude variation (coefficie

Hypothesis

The brain's epigenetic aging trajectory is not self-determined but is continuously calibrated by gut-derived metabolites transmitted via vagal afferent signaling. This implies that longevity interventions must first reprogram gut microbial metabolism to produce specific metabolites that act as epigenetic modulators in the brain, effectively resetting neuronal aging clocks.

Mechanistic Reasoning

Current gut-brain axis research confirms unidirectional causality: gut microbiota alterations drive brain aging via metabolites and vagal afferents Microbiome depletion rejuvenates the aging brain. But we're missing the finer mechanism. Gut metabolites like butyrate and indoles aren't just anti-inflammatory—they likely serve as direct epigenetic regulators when they reach the brain via the vagus nerve.

Vagal afferents from the gut terminate in the nucleus tractus solitarius (NTS), which projects to the hippocampus and amygdala The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. These pathways use neurotransmitters like glutamate and neuropeptides. The novel twist: gut-derived metabolites, sensed by enteroendocrine cells, trigger vagal firing patterns that may release neuropeptides in the NTS, which then directly modulate histone deacetylase (HDAC) activity or DNA methyltransferase expression in connected brain regions. For instance, butyrate is a known HDAC inhibitor—but its systemic effects are blunted

Current trials measure berberine's effect via fasting glucose and HbA1c, but these metrics obscure the real-time dynamics where its mechanism likely operates. The primary action is AMPK activation and inhibition of mitochondrial complex I, shifting metabolism toward glucose uptake and lipid oxidation (Frontiers in Pharmacology, 2022). This is a systemic, energy-sensing response, not a direct insulin secretagogue effect. Hypothesis: Berberine's clinical efficacy in lowering HbA1c is driven predominantly by its acute suppression of postprandial glucose excursions, not by altering baseline fasting glucose. Furthermore, CGM will reveal that 'responder' status is predicted by a high baseline amplitude of postprandial spikes (>40 mg/dL from pre-meal baseline).

The mechanistic reasoning is twofold:

1. Energy Demand Coupling: AMPK activation is most physiologically relevant when cellular energy demand is high—i.e., in the postprandial state. Berberine's effect may be preferential for glucose disposal during these periods of influx. The 2022 meta-analysis showed stronger effects at higher baseline glucose, but discrete measurements can't distinguish whether this is due to elevated fasting levels or more severe postprandial spikes.
2. Gut-Mediated Signaling: Berberine's poor bioavailability (<1%, PubMed) means a high concentration acts directly on the gut epithelium and microbiome. This can modulate GLP-1 secretion and glucose absorption kinetics. Individuals with larger postprandial spikes may have a gut environment (e.g.,

Background

Anti-MDA5-positive dermatomyositis carries 30–50% mortality from rapidly progressive interstitial lung disease (RP-ILD), yet current prediction relies on static biomarker thresholds (ferritin >1500 ng/mL, KL-6) measured at single time points. Galectin-9 (Gal-9), a tandem-repeat lectin released by activated macrophages and dendritic cells, has emerged as a marker of innate immune activation in autoimmune ILD but has not been evaluated as a dynamic trajectory biomarker.

Hypothesis

Serial serum Gal-9 measurements modeled as a linear mixed-effects trajectory, combined with anti-MDA5 antibody titer and baseline HRCT ground-glass opacity extent, will predict RP-ILD onset (defined as ≥10% FVC decline within 4 weeks) with >85% sensitivity and >75% specificity, 4–8 weeks before respiratory deterioration becomes clinically apparent.

Mechanistic Rationale

Gal-9 is secreted by alveolar macrophages during TIM-3/Gal-9 pathway activation, which drives Th1 apoptosis and regulatory T-cell expansion. In MDA5+ DM, aberrant type I interferon signaling upregulates Gal-9 production disproportionately. A rising Gal-9 slope reflects escalating alveolar macrophage activation — the pathological driver of RP-ILD — before pulmonary function tests detect functional decline.

Testable Predictions

1. Primary: Gal-9 slope >2.0 ng/mL/week over 3+ serial measurements predicts RP-ILD onset (AUC >0.85) when combined with MDA5 titer in a joint longitudinal-survival model
2. Secondary: Gal-9 trajectory inflection point precedes FVC decline by a median of 6 weeks (95% CI: 4–8

The pronounced sex bias in age-related somatic hypermutation (SHM) decline—where males show steeper reductions in Phase II repair activity and mismatch repair (MMR) gene expression (Aged males exhibit a more pronounced decline in SHM-related DNA repair activities compared to females)—points to a specific, testable mechanistic failure beyond general B-cell dysfunction. Current models attribute SHM decline to diminished AID function and extrinsic GC dysfunction (Age-associated dysfunction in germinal centers contributes to poor affinity maturation and reduced class-switching). However, these models don't adequately explain why the MMR-dependent Phase II (targeting A/T bases) is disproportionately affected in males.

Hypothesis: The sex-biased decline in SHM is driven by cumulative, sex-specific oxidative damage to key MMR proteins (particularly MSH2-MSH6 and PMS2-POLη complexes) in male B cells, reducing their recruitment and processivity at AID-induced lesions. This is compounded by a relative deficit in oxidative stress defense pathways within male GC B cells, leading to the accumulation of irreversible protein adducts (e.g., 4-hydroxynonenal [4-HNE] modifications) on MMR components.

Novel Mechanistic Reasoning:

1. Oxidative Protein Modification as a Specific Driver: SHM occurs in the oxidative environment of the GC. MMR proteins are redox-sensitive. Males, due to hormonal differences (e.g., lower estrogen, which has antioxidant and DNA repair-enhancing ef

Recent evidence highlights a dual-pathway for NLRP3 activation in aging: mechanical priming via Piezo1-mediated mechanosensing [PMC12965337] and biochemical feedback loops involving extracellular ASC specks and SASP-induced NF-κB activation [PMC12517589]. While the field has traditionally separated "Signal 1" (priming) and "Signal 2" (activation/K⁺ efflux), the persistent hyper-inflammatory state of aged macrophages suggests these signals may be physically coupled through the cell’s structural architecture.

I've been looking at Senescent-Associated Mechanical Remodeling (SAMR)—specifically the increase in nuclear volume and cytoskeletal stiffness associated with distinct senescence motifs [10.1126/sciadv.ads1875]—and I suspect it creates a state of chronic membrane tension that acts as a physical rheostat. This tension doesn't merely "prime" the NLRP3 complex via IKKβ; it physically lowers the activation energy required for K⁺ efflux through mechanosensitive potassium channels like TWIK2. In effect, it turns the aging inflammasome into a "brittle" trigger.

The mechanism likely works like this: In aged macrophages, altered mitochondrial-ER contact sites (MERCs) and increased nuclear size [10.1126/sciadv.ads1875] redistribute intracellular strain to the plasma membrane. Piezo1 then activates in response to this internal crowding or external shear stress, inducing canonical NF-κB priming [PMC12965337]. However, Piezo1 activity likely also recruits and clusters K⁺ channels at the membrane through lipid raft reorganization. This clustering, combined with high basal membrane te

Sleep-dependent glymphatic clearance looks less like a passive metabolic rinse and more like a high-fidelity triage mechanism. In this view, the clearance of specific morphogens—like C1q, pro-inflammatory cytokines, and metabolic byproducts—dictates which synaptic architectures are pruned and which are stabilized. The age-related failure of this "neural autopsy" isn't necessarily an intrinsic brain defect. Instead, it’s likely driven by a systemic bottleneck: senescence-induced dysfunction of the deep cervical lymph nodes (dCLNs), triggered by the inflammatory outflow from a collapsing Gut-Associated Lymphoid Tissue (GALT).

The brain isn't failing to edit itself because of internal defects; the "drainage pipes" in the neck are functionally paralyzed by systemic SASP factors originating in the gut. We know the gut is the primary site of age-related immune exhaustion. M-cell density in aged Peyer's patches drops by about 30% (PMC3747980), and isolated lymphoid follicles show a sharp decline in CXCL13/CCL20 expression (PMC3023758). This GALT collapse creates a chronic inflammatory state—evidenced by the fact that aging tissue exhibits hundreds of upregulated genes enriched for SASP and immune activation (PMC11408255).

This systemic tide of IL-6, TNF-α, and MMPs directly antagonizes the nitric oxide and adrenergic signaling the cervical lymphatic endothelium needs to contract rhythmically. Because the [nasopharyngeal l

Background

Longitudinal rheumatology data are inherently irregular: patients visit at variable intervals, measurements are missing not-at-random, and disease dynamics operate in continuous time. Yet standard predictive models (logistic regression, random forests, LSTMs) discretize time into fixed windows, discarding information about visit timing and imposing artificial synchronization across patients.

Neural Ordinary Differential Equations (Neural ODEs) parameterize the derivative of a latent state as a neural network, solving the initial value problem via numerical integration. This allows learning continuous-time dynamics from irregularly sampled observations — a natural fit for real-world rheumatology cohorts.

Hypothesis

We hypothesize that a Neural ODE model trained on irregularly sampled longitudinal data (DAS28 components, ESR/CRP, RF/ACPA titers, medication history, and visit timestamps) will:

1. Learn continuous latent disease trajectories that capture nonlinear dynamics missed by discrete models
2. Predict DAS28 remission (DAS28 <2.6) at 12 weeks with AUROC ≥0.82 and calibration slope within [0.85, 1.15]
3. Outperform GRU-D and time-aware LSTM baselines by ≥5% in AUROC on held-out data with >30% missing visit irregularity
4. Generate interpretable phase portraits in the learned latent space showing attractor basins corresponding to remission vs. persistent activity

Proposed Methodology

Acarbose extends lifespan robustly in male mice, but the mechanistic basis for its sex-specific benefits remains unclear. This hypothesis proposes that acarbose-induced gut microbiome restructuring enhances portal butyrate production, which subsequently upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and cortex, driving neuroprotective effects that mediate lifespan extension. Critically, this pathway is sex-dimorphic due to estrogen receptor beta (ERβ)-mediated suppression of BDNF transcription in females, explaining the male-biased longevity response.

Mechanistic Rationale

Acarbose inhibits alpha-glucosidase, diverting undigested carbohydrates to the distal gut where they fuel butyrate-producing Firmicutes [https://pmc.ncbi.nlm.nih.gov/articles/PMC9286917/]. Butyrate, a histone deacetylase (HDAC) inhibitor, can cross the blood-brain barrier and epigenetically enhance BDNF promoter activity. BDNF activation in the central nervous system promotes neuronal survival, synaptic plasticity, and autophagy—key processes in aging. The strong synergy between acarbose and rapamycin [https://www.gethealthspan.com/research/article/top-ten-longevity-anti-aging-breakthroughs-of-2025] may stem from rapamycin's mTOR inhibition potentiating BDNF-induced autophagy, creating a compounded proteostatic benefit.

The sex disparity likely arises from hormonal modulation of BDNF signaling. Estrogen, via ERβ, represses BDNF transcription in females, whereas testosterone in males may amplify it. This aligns with the pronounced lifespan effects in male mice [htt

IF a sequentially-phased triple-combination regimen of Urolithin A (50 mg/kg/day, oral gavage, weeks 1–8), AICAR (500 mg/kg/day, intraperitoneal injection, weeks 3–8), and GW501516 (5 mg/kg/day, oral gavage, weeks 3–8) — with urolithin A administered as a two-week mitophagy primer before the biogenesis-driving mimetics are introduced — is administered to frail, exercise-intolerant 24-month-old male C57BL/6J mice (confirmed frail by Frailty Index ≥ 0.45 and grip-strength < 20th percentile for age-matched cohort),

THEN compared to vehicle control, age-matched voluntary wheel runners, and non-sequenced simultaneous triple-combination controls, the sequenced regimen will produce: (1) ≥40% reduction in skeletal muscle mtDNA deletion heteroplasmy (gastrocnemius, measured by long-range PCR and digital droplet PCR), (2) ≥35% increase in mtDNA copy number normalized to nuclear DNA (COX2/β-globin ratio, qPCR), (3) ≥2-fold increase in PINK1 and LC3-II protein in muscle relative to vehicle control (Western blot), (4) ≥25% increase in Pax7⁺/MyoD⁺ co-positive satellite cells per fiber cross-section (immunofluorescence, tibialis anterior), (5) ≥20% improvement in grip strength and rotarod latency-to-fall relative to vehicle control, measured at week 8 endpoint, and these outcomes will exceed those of simultaneously-dosed triple-combination controls by ≥15%, demonstrating that sequence—not merely pharmacological co-presence—is mechanistically critical,

BECAUSE the following causal chain is proposed:

1. Mitophagy priming clears the substrate before biogenesis replenishes it. Urolithi

Hypothesis: Age-related hearing loss may reflect tissue-specific antagonistic pleiotropy. In this framework, developmental growth programs—particularly insulin-like growth factor-1 (IGF-1) signaling—persist in the adult cochlea at levels that paradoxically accelerate cellular senescence. Rather than viewing presbycusis as passive accumulation of stochastic damage, spiral ganglion neuron attrition and strial degeneration follow predictions from pleiotropic trade-off models: the cochlea's exceptionally high metabolic demand makes it particularly vulnerable when resources shift away from post-reproductive maintenance toward other fitness priorities.

Mechanistic Framework: IGF-1 signaling demonstrates well-known pleiotropic effects. During development, it promotes neuronal survival and myelination, yet continued receptor activation in aged tissue drives cellular senescence and inflammation. The cochlea faces unique energetic challenges—spiral ganglion neurons can fire at rates approaching 1000 spikes per second, requiring substantial ATP for ion homeostasis. When age-related systemic metabolic shifts occur alongside declining anabolic signaling, the cochlea may experience what I'll call an IGF-1 "overshoot." Developmental programs that should be downregulated persist, triggering mTOR activation, oxidative stress amplification, and senescent secretome propagation.

Testable Predictions: First, species carrying higher-activity IGF-1 alleles should show accelerated presbycusis compared to lifespan-matched species with lower-activity variants—comparing mice to long-liv

Claim: When perp funding rate is in the extreme positive tail (e.g., top 1–5% of its 30–90d distribution), the next 6–12 hours of spot returns are negative on average (mean reversion).

Rationale: Extreme positive funding indicates overcrowded long positioning. As funding cost spikes, marginal longs de-risk, and short-term liquidity becomes one-sided, increasing vulnerability to squeeze/reversal.

Test:

1. Define extreme funding as funding rate > P95 (or P99) of trailing 90d for each market.
2. For each extreme event, compute forward spot returns at +6h and +12h.
3. Compare to baseline unconditional returns and to non-extreme periods.

Metrics:

• Mean forward return (t-test / bootstrap CI)
• Hit rate (P[return < 0])
• Effect size vs. baseline

Falsifier: If forward returns are not significantly negative (or are positive) after extreme funding spikes, the hypothesis fails.